NASDAQ:AVRO

AVROBIO - AVRO Stock Forecast, Price & News

$1.04

-0.02 (-1.89%)

(As of 08/11/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.01
▼
$1.07
50-Day Range: $0.86
▼
$1.07
52-Week Range: $0.74
▼
$6.88

Volume: 110,971 shs
Average Volume: 592,116 shs
Market Capitalization: $45.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.29

AVROBIO MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 408.2% Upside
$5.29 Price Target
Short Interest: Healthy
1.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.45
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.14) to ($1.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

274th out of 1,112 stocks

Biological Products, Except Diagnostic Industry

44th out of 175 stocks

3.3

Analyst's Opinion

Consensus Rating
AVROBIO has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.29, AVROBIO has a forecasted upside of 408.2% from its current price of $1.04.
Amount of Analyst Coverage
AVROBIO has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.10% of the float of AVROBIO has been sold short.
Short Interest Ratio / Days to Cover
AVROBIO has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AVROBIO has recently decreased by 10.08%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
AVROBIO does not currently pay a dividend.
Dividend Growth
AVROBIO does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVRO.

2.5

News and Social Media Coverage

News Sentiment
AVROBIO has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for AVROBIO this week, compared to 2 articles on an average week.
MarketBeat Follows
3 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVROBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.40% of the stock of AVROBIO is held by insiders.
Percentage Held by Institutions
63.92% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for AVROBIO are expected to grow in the coming year, from ($2.14) to ($1.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVROBIO is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVROBIO is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVROBIO has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AVROBIO (NASDAQ:AVRO) Stock

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVROBIO Stock Up 5.0 %

Shares of AVRO opened at $1.06 on Thursday. AVROBIO has a twelve month low of $0.74 and a twelve month high of $6.88. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 0.10. The company has a 50 day moving average of $0.97 and a 200-day moving average of $1.19.

AVROBIO (NASDAQ:AVRO - Get Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). On average, sell-side analysts predict that AVROBIO will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on AVRO shares. Barclays cut their price objective on AVROBIO from $6.00 to $4.00 in a research report on Wednesday, May 11th. Wedbush dropped their price target on shares of AVROBIO from $14.00 to $4.00 in a research note on Wednesday, May 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $5.29.

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Stock News Headlines

August 9, 2022 | benzinga.com

Recap: Avrobio Q2 Earnings - Benzinga

August 9, 2022 | businesswire.com

AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update - Business Wire

August 9, 2022 | msn.com

Recap: Avrobio Q2 Earnings

August 4, 2022 | finance.yahoo.com

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights - Yahoo Finance

August 1, 2022 | businesswire.com

AVROBIO to Participate in Two Upcoming Investor Conferences in August - Business Wire

August 1, 2022 | finance.yahoo.com

AVROBIO to Participate in Two Upcoming Investor Conferences in August

July 21, 2022 | americanbankingnews.com

AVROBIO, Inc. (NASDAQ:AVRO) Receives $5.29 Consensus Price Target from Brokerages

July 13, 2022 | benzinga.com

AVROBIO Receives Orphan Drug Designation From The US FDA For AVR-RD-05, A Gene Therapy For Mucopolysaccharidosis Type II Or Hunter Syndrome - Benzinga

July 13, 2022 | benzinga.com

AVROBIO Receives Orphan Drug Designation from the US Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome - Benzinga

July 13, 2022 | finance.yahoo.com

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

June 16, 2022 | seekingalpha.com

BioLineRx hires Avrobio exec as chief commercial officer to bolster cancer therapy efforts - Seeking Alpha

June 11, 2022 | seekingalpha.com

With bluebird bio's success, what are other gene therapies companies to pay attention to? - Seeking Alpha

May 19, 2022 | nasdaq.com

What Is The Relative Strength Index (RSI) In Stocks? - Nasdaq

May 18, 2022 | nasdaq.com

Investors Heavily Search Chevron Corporation (CVX): Here is What You Need to Know - Nasdaq

May 18, 2022 | finance.yahoo.com

Hospital Privacy Screens Market Size & Share [2022-2029] | Industry Analysis, Growth, Trends, Revenue by Fortune Business Insights - Yahoo Finance

May 18, 2022 | businesswire.com

AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business Wire

May 18, 2022 | finance.yahoo.com

AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 17, 2022 | marketwatch.com

Avrobio Shares Rise on Encouraging Clinical Trial Data - MarketWatch

May 17, 2022 | finance.yahoo.com

AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

May 17, 2022 | finance.yahoo.com

AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures - Yahoo Finance

May 17, 2022 | finance.yahoo.com

AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

May 16, 2022 | businesswire.com

AVROBIO to Present at the H.C. Wainwright Global Investment Conference - Business Wire

May 16, 2022 | benzinga.com

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And Mo - Benzinga

May 16, 2022 | benzinga.com

AVROBIO to Present at the H.C. Wainwright Global Investment Conference - Benzinga - Benzinga

May 16, 2022 | finance.yahoo.com

AVROBIO to Present at the H.C. Wainwright Global Investment Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Company Calendar

Last Earnings: 8/09/2022
Today: 8/11/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVRO
CUSIP: N/A
CIK: 1681087
Web: www.avrobio.com
Phone: (617) 914-8420
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.29
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +408.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -70.36%
Return on Assets: -59.80%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 9.98
Quick Ratio: 9.98

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.88 per share
Price / Book: 0.27

Miscellaneous

Outstanding Shares: 43,696,000
Free Float: 40,899,000
Market Cap: $45.44 million
Optionable: Not Optionable
Beta: 1.56

Key Executives

Mr. Geoff MacKay BSc (Age 56)
Co- Founder, Pres, CEO & Director
Comp: $754.39k
Mr. Erik John Ostrowski M.B.A. (Age 49)
CFO & Treasurer
Comp: $554.66k
Mr. Jeffrey Medin Ph.D.
Scientific Founder
Mr. Matthew Arnold
Head of Operations
Mr. Steven N. Avruch J.D. (Age 61)
Chief Legal Officer & Sec.
Ms. Monique Da Silva
Sr. VP of Corp. Communications
Ms. Deanna M. Petersen MBA (Age 60)
Chief Bus. Officer
Ms. Azadeh Golipour Ph.D.
Chief Technology Officer
Mr. Andreas Kouri
Sr. VP of Global Supply Chain & External Manufacturing
Dr. Essra Ridha FFPM
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVRO Stock - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVRO shares.
View AVRO analyst ratings or view top-rated stocks.
What is AVROBIO's stock price forecast for 2022?: 6 Wall Street analysts have issued 12 month target prices for AVROBIO's stock. Their AVRO share price forecasts range from $3.00 to $8.00. On average, they expect the company's share price to reach $5.29 in the next year. This suggests a possible upside of 398.7% from the stock's current price.
View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts.
How have AVRO shares performed in 2022?: AVROBIO's stock was trading at $3.85 at the beginning of the year. Since then, AVRO stock has decreased by 72.5% and is now trading at $1.06.
View the best growth stocks for 2022 here.
When is AVROBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AVRO earnings forecast.
How were AVROBIO's earnings last quarter?: AVROBIO, Inc. (NASDAQ:AVRO) posted its quarterly earnings data on Tuesday, August, 9th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.07.
What other stocks do shareholders of AVROBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

When did AVROBIO IPO?: (AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.
What is AVROBIO's stock symbol?: AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."
Who are AVROBIO's major shareholders?: AVROBIO's stock is owned by a number of institutional and retail investors. Top institutional investors include GMT Capital Corp (8.00%), JPMorgan Chase & Co. (4.85%), Private Advisor Group LLC (0.18%) and Sawtooth Solutions LLC (0.17%). Insiders that own company stock include Christopher Paige, Geoffrey Mackay and Philip J Vickers.
View institutional ownership trends.
How do I buy shares of AVROBIO?: Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AVROBIO's stock price today?: One share of AVRO stock can currently be purchased for approximately $1.06.
How much money does AVROBIO make?: AVROBIO (NASDAQ:AVRO) has a market capitalization of $46.32 million. The company earns $-119,130,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.
How many employees does AVROBIO have?: The company employs 122 workers across the globe.
How can I contact AVROBIO?: AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The official website for the company is www.avrobio.com. The company can be reached via phone at (617) 914-8420 or via email at ir@ampliphibio.com.

This page (NASDAQ:AVRO) was last updated on 8/12/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

AVROBIO - AVRO Stock Forecast, Price & News

AVROBIO MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AVROBIO (NASDAQ:AVRO) Stock

AVROBIO Stock Up 5.0 %

Wall Street Analyst Weigh In

AVRO Stock News Headlines

AVRO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AVRO Stock - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?

What is AVROBIO's stock price forecast for 2022?

How have AVRO shares performed in 2022?

When is AVROBIO's next earnings date?

How were AVROBIO's earnings last quarter?

What other stocks do shareholders of AVROBIO own?

When did AVROBIO IPO?

What is AVROBIO's stock symbol?

Who are AVROBIO's major shareholders?

How do I buy shares of AVROBIO?

What is AVROBIO's stock price today?

How much money does AVROBIO make?

How many employees does AVROBIO have?

How can I contact AVROBIO?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™